Michael P Krensavage, Executive Officer, Promoter at Krensavage Partners, New York — verified investor profile. See sector focus and contact routes.
Michael P. Krensavage is the founder and Chief Executive Officer and Managing Member of Krensavage Asset Management in New York, and he is listed in a 2026 filing as an executive officer and promoter of Krensavage Partners LP. Krensavage Partners is described as a healthcare-focused hedge fund and value-oriented investment partnership managed by Krensavage Asset Management. Public sources identify its strategy as long/short equity in U.S. healthcare, but do not clearly verify stage focus, geography beyond the United States, or a broader private-equity style mandate. One fund database lists a minimum investment of $500,000 and roughly $256.7 million in assets, but I could not verify a standard check size or lead/follow behavior. Named holdings and portfolio companies reported in public sources include Regeneron Pharmaceuticals, Taro Pharmaceutical Industries, Alkermes, Gilead Sciences, Elanco Animal Health, Biogen, United Therapeutics, Cardinal Health, Exelixis, Jazz Pharmaceuticals, and Enanta Pharmaceuticals. A 2019 writeup said the partnership had produced strong cumulative net returns since its 2008 inception and that it benchmarks against the S&P H
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Michael P Krensavage · Full investor directory · Investor access · Company funding database